Takeda signed a multiyear discovery and technology collaboration with Iambic Therapeutics to deploy Iambic’s generative AI tools across small‑molecule programs in oncology, GI and inflammation. The deal positions Takeda to integrate AI‑driven design into early discovery workflows and signals continued pharma investment in algorithmic molecule generation. Takeda framed the collaboration as part of a broader strategy to ‘fully integrate’ AI into drug discovery, echoing comments from company R&D leadership. The arrangement may include technology access, target discovery and co‑development elements intended to de‑risk early programs and accelerate candidate selection. The partnership is part of a wave of pharma‑AI agreements that span both computational design and downstream experimental validation, testing whether AI can materially shorten lead‑generation timelines at scale.